MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS

雌激素提高血浆 APO A1 水平的机制

• 批准号: 6114458
• 负责人: ERNST JOHN SCHAEFER
• 金额: $ 4.27万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114458
• 关键词: apolipoproteins; blood lipoprotein metabolism; clinical research; coronary disorder; disease /disorder proneness /risk; estrogens; female; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; medroxyprogesterone; postmenopause

Postmenopausal women are at higher risk of coronary heart disease (CHD) than premenopausal women, even after controlling for age-effects. However, estrogen replacement therapy significantly lowers the risk of CHD in postmenopausal women. With the study, we propose to determine the kinetics of apolipoprotein A-1, the major protein component of high density lipoproteins, in postmenopausal women undergoing a placebo-controlled, randomized treatment with each of the following regimens: a. placebo; b. 0.625mg/d conjugated estrogens; c. 0.625mg/d conjugated estrogens + 2.5 mg/d medroxyprogesterone acetate. The kineetics of apo A-1 will be determined by stable isotope techniques. The low dose estrogen (b) and the estrogen-progestin combination (c) are frequently prescribed to postmenopausal women as hormone replacement therapy, but there are metabolism and apolipoprotein kinetics.

即使在控制了年龄影响后，绝经后女性患冠心病（CHD）的风险也高于绝经前女性。 然而，雌激素替代疗法可显着降低绝经后女性患冠心病的风险。 通过这项研究，我们建议确定绝经后妇女中载脂蛋白 A-1（高密度脂蛋白的主要蛋白质成分）的动力学，这些妇女接受以下每种方案的安慰剂对照、随机治疗：安慰剂； b. 0.625mg/d结合雌激素； c. 0.625mg/d 结合雌激素 + 2.5 mg/d 醋酸甲羟孕酮。 apo A-1 的动力学将通过稳定同位素技术测定。低剂量雌激素 (b) 和雌激素-孕激素组合 (c) 经常作为激素替代疗法用于绝经后妇女，但存在代谢和载脂蛋白动力学问题。